Wasatch BioLabs
Private Company
Total funding raised: $1.8M
Overview
Wasatch BioLabs is a specialized service provider in the genetics and genomics sector, built around proprietary long-read sequencing platforms for integrated genomic and epigenomic data. Its core innovation is the Direct Whole Methylome Sequencing (dWMS) platform, which enables bisulfite-free, PCR-free methylation analysis alongside variant detection. Positioning itself as the first full-scale clinical lab dedicated to Oxford Nanopore sequencing, the company targets the high-growth areas of precision health, biomarker discovery, and scalable clinical assay deployment.
Technology Platform
Proprietary long-read sequencing platforms (Direct Whole Methylome Sequencing - dWMS, Direct Targeted Methylation Sequencing - dTMS) built on Oxford Nanopore Technology, enabling bisulfite-free, PCR-free co-detection of DNA methylation and genetic variants from native DNA.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Wasatch BioLabs competes with large, diversified genomics CROs (e.g., Azenta, Quintara) and diagnostic service labs, as well as other specialists in long-read sequencing. Its key differentiation is its proprietary focus on bisulfite-free, native methylation sequencing coupled with variant detection, a niche not fully addressed by competitors relying on short-read or traditional bisulfite methods.